Bringing the fundamentals into focus…
Back to Climb Bio, Inc.
How Climb Bio, Inc. stacks up
CLYM · against 552 other Healthcare companies listed in US-listed
Overall
42/ 100
Below the middle of the pack.
Ranked #279 of 553 · scores higher than 48% of peers
Bars: peers in each 10-point band of the overall score101 peers with an overall score of 40–49, including CLYM · Click a bar to see the companies
The four scores behind it
Overall = average of valuation, growth, profitability and safety percentile (categories without data are skipped)Ranking by overall score
Top 5 and the companies ranked around CLYM| Rank | Company | Market cap | Overall | Valuation | Growth | Profitability | Risk |
|---|---|---|---|---|---|---|---|
| 1 | 595M USD | 97 | 96 | 98 | 99 | 0 / 2 | |
| 1 | 261M USD | 97 | 93 | — | 98 | 0 / 2 | |
| 3 | 2.1B USD | 96 | 96 | 99 | 93 | 0 / 2 | |
| 4 | 1.5B USD | 93 | 94 | 91 | 93 | 0 / 2 | |
| 5 | 609M USD | 91 | 95 | 99 | 99 | 0 / 2 | |
| 267 | 2.6B USD | 43 | 8 | — | 21 | 0 / 2 | |
| 267 | 3.6B USD | 43 | 85 | 15 | 69 | 2 / 2 | |
| 267 | 1.6B USD | 43 | 39 | 90 | 33 | 2 / 2 | |
| 279 | 1.2B USD | 42 | 40 | 65 | 41 | 2 / 2 | |
| 279 | 560M USD | 42 | 8 | — | 21 | 0 / 2 | |
| 279 | 1.4B USD | 42 | 68 | 28 | 52 | 2 / 2 | |
| 279 | 4.1B USD | 42 | 8 | — | 22 | 0 / 2 | |
| 279 | 1.8B USD | 42 | 8 | — | 20 | 0 / 2 | |
| 279 | 302M USD | 42 | 8 | 90 | 10 | 1 / 2 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score